1
|
Gailllard B, Cornillet-Lefebvre P, Le QH, Maloum K, Pannetier M, Lecoq-Lafon C, Grange B, Jondreville L, Michaux L, Nadal N, Ittel A, Luquet I, Struski S, Lefebvre C, Gaillard JB, Lafage-Pochitaloff M, Balducci E, Penther D, Barin C, Collonge-Rame MA, Jimenez-Poquet M, Richebourg S, Lemaire P, Defasque S, Radford-Weiss I, Bidet A, Susin SA, Nguyen-Khac F, Chapiro E. Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. Br J Haematol 2020; 193:72-82. [PMID: 33314017 DOI: 10.1111/bjh.17141] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 09/04/2020] [Accepted: 09/09/2020] [Indexed: 01/16/2023]
Abstract
A translocation involving the cyclin-dependent kinase 6 (CDK6) gene [t(CDK6)] is a rare but recurrent abnormality in B-cell neoplasms. To further characterise this aberration, we studied 57 cases; the largest series reported to date. Fluorescence in situ hybridisation analysis confirmed the involvement of CDK6 in all cases, including t(2;7)(p11;q21) immunoglobulin kappa locus (IGK)/CDK6 (n = 51), t(7;14)(q21;q32) CDK6/immunoglobulin heavy locus (IGH) (n = 2) and the previously undescribed t(7;14)(q21;q11) CDK6/T-cell receptor alpha locus (TRA)/T-cell receptor delta locus (TRD) (n = 4). In total, 10 patients were diagnosed with chronic lymphocytic leukaemia, monoclonal B-cell lymphocytosis or small lymphocytic lymphoma, and 47 had small B-cell lymphoma (SmBL) including 36 cases of marginal zone lymphoma (MZL; 34 splenic MZLs, one nodal MZL and one bronchus-associated lymphoid tissue lymphoma). In all, 18 of the 26 cytologically reviewed cases of MZL (69%) had an atypical aspect with prolymphocytic cells. Among the 47 patients with MZL/SmBL, CD5 expression was found in 26 (55%) and the tumour protein p53 (TP53) deletion in 22 (47%). The TP53 gene was mutated in 10/30 (33%); the 7q deletion was detected in only one case, and no Notch receptor 2 (NOTCH2) mutations were found. Immunoglobulin heavy-chain variable-region (IGHV) locus sequencing revealed that none harboured an IGHV1-02*04 gene. Overall survival was 82% at 10 years and not influenced by TP53 aberration. Our present findings suggest that most t(CDK6)+ neoplasms correspond to a particular subgroup of indolent marginal zone B-cell lymphomas with distinctive features.
Collapse
Affiliation(s)
| | | | - Quoc-Hung Le
- Service d'Hématologie Clinique, Hôpital Robert Debré, Reims, France
| | - Karim Maloum
- Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France
| | - Mélanie Pannetier
- Laboratoire d'Hématologie, Centre Hospitalo-Universitaire, Rennes, France
| | | | - Béatrice Grange
- Service d'Hématologie Biologique, Hospices Civils de Lyon, Lyon, France
| | - Ludovic Jondreville
- Centre de Recherche des Cordeliers, INSERM UMRS_1138, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Paris, France
| | - Lucienne Michaux
- Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
| | - Nathalie Nadal
- Service de génétique chromosomique et moléculaire, CHU Dijon, France
| | - Antoine Ittel
- Laboratoire de Cytogénétique Hématologique, CHU de Strasbourg, Strasbourg, France
| | - Isabelle Luquet
- Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Stéphanie Struski
- Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | | | | | - Marina Lafage-Pochitaloff
- Laboratoire de Cytogénétique Onco-Hématologique, Hôpital de la Timone, AP-HM, Aix-Marseille Université, Marseille, France
| | - Estelle Balducci
- Laboratoire d'Hématologie, Hôpital Paul Brousse, APHP, Villejuif, France
| | - Dominique Penther
- Laboratoire de Génétique Oncologique, CLCC Henri Becquerel and INSERM U1245, Rouen, France
| | - Carole Barin
- Laboratoire de Cytogénétique hématologique, Service de Génétique, CHRU Bretonneau, Tours, France
| | | | | | - Steven Richebourg
- Laboratoire de Cytogénétique Onco-Hématologique, CHU de Québec - Université Laval, Québec, Canada
| | - Pierre Lemaire
- Laboratoire d'Hématologie, Hôpital Saint-Louis, APHP, Paris, France
| | - Sabine Defasque
- Secteur cytogénétique hématologique, Laboratoire CERBA, Saint-Ouen l'Aumône, France
| | | | - Audrey Bidet
- Laboratoire d'Hématologie, CHU Bordeaux-Haut Lévêque, Bordeaux, France
| | - Santos A Susin
- Centre de Recherche des Cordeliers, INSERM UMRS_1138, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Paris, France.,Sorbonne Université, Paris, France
| | - Florence Nguyen-Khac
- Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.,Centre de Recherche des Cordeliers, INSERM UMRS_1138, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Paris, France.,Sorbonne Université, Paris, France
| | - Elise Chapiro
- Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.,Centre de Recherche des Cordeliers, INSERM UMRS_1138, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Paris, France.,Sorbonne Université, Paris, France
| | | |
Collapse
|